This clinical trial is focused on studying the effects of a medication called remibrutinib on a skin condition known as hidradenitis suppurativa. Hidradenitis suppurativa is a chronic skin disease that causes small, painful lumps to form under the skin, often in areas where the skin rubs together. The study will compare the effectiveness of remibrutinib to a placebo, which is a substance with no active medication, to see if remibrutinib can help reduce the symptoms of this condition.
The purpose of the study is to assess how well remibrutinib works in reducing the number of painful lumps and abscesses in patients with moderate to severe hidradenitis suppurativa. Participants in the study will receive either remibrutinib or a placebo over a period of 68 weeks. The study will also involve the use of other medications, such as clindamycin hydrochloride, a type of antibiotic, and triamcinolone acetonide, a medication used to reduce inflammation. These medications will be administered to help manage the symptoms of the disease.
Throughout the study, participants will be monitored to evaluate the safety and tolerability of remibrutinib. The study aims to determine if remibrutinib can achieve a significant reduction in the symptoms of hidradenitis suppurativa, such as a decrease in the number of abscesses and inflammatory nodules. The results will help to understand if remibrutinib is a viable treatment option for individuals suffering from this challenging skin condition.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Poland 
Romania 
Spain 
